In fiscal year 2023 — Oct. 1–Sept. 30, 2023 — Oak Ridge National Laboratory was awarded more than $8 million in technology maturation funding through the Department of Energy’s Technology Commercialization Fund, or TCF.
ORNL, a bastion of nuclear physics research for the past 80 years, is poised to strengthen its programs and service to the United States over the next decade if national recommendations of the Nuclear Science Advisory Committee, or NSAC, are enacted.
ORNL’s Fulvia Pilat and Karren More recently participated in the inaugural 2023 Nanotechnology Infrastructure Leaders Summit and Workshop at the White House.
Speakers, scientific workshops, speed networking, a student poster showcase and more energized the Annual User Meeting of the Department of Energy’s Center for Nanophase Materials Sciences, or CNMS, Aug. 7-10, near Market Square in downtown Knoxville, Tennessee.
Neutron experiments can take days to complete, requiring researchers to work long shifts to monitor progress and make necessary adjustments. But thanks to advances in artificial intelligence and machine learning, experiments can now be done remotely and in half the time.
ORNL will team up with six of eight companies that are advancing designs and research and development for fusion power plants with the mission to achieve a pilot-scale demonstration of fusion within a decade.
Growing up in China, Yue Yuan stood beneath the world’s largest hydroelectric dam, built to harness the world’s third-longest river. Her father brought her to Three Gorges Dam every year as it was being constructed across the Yangtze River so she could witness its progress.
ORNL researchers used the nation’s fastest supercomputer to map the molecular vibrations of an important but little-studied uranium compound produced during the nuclear fuel cycle for results that could lead to a cleaner, safer world.
A study led by researchers at ORNL could help make materials design as customizable as point-and-click.
An ORNL-led team comprising researchers from multiple DOE national laboratories is using artificial intelligence and computational screening techniques – in combination with experimental validation – to identify and design five promising drug therapy approaches to target the SARS-CoV-2 virus.